Für die Behandlung von progredient fibrosierenden interstitiellen #Lungenerkrankungen gibt es schon zugelassene Wirkstoffe, etwa Nintedanib und Pirfenidon. Dennoch besteht Bedarf an weiteren Therapieoption. Eine solche könnte mit Nerandomilast in absehbarer Zeit zur Verfügung stehen.
Interstitielle Lungenerkrankungen: Nerandomilast überzeugt in Phase III
Phase-III-Studiendaten zeigen, dass der neue Wirkstoff Nerandomilast den Rückgang der Lungenfunktion bei idiopathischer Lungenfibrose und progred...
www.pharmazeutische-zeitung.de
June 5, 2025 at 1:24 PM
Everybody can reply
#ILDSky #CureIPF #CurePF
Nintedanib for SSc-ILD at Scleroderma centres in the US.
Not one 🫁 MD on this paper 👀
Are Rheumatologists treating/managing ILD at your centres?
@jskim8223.bsky.social @ipfdoc.bsky.social @tkulkarni.bsky.social @istamina.bsky.social
Nintedanib for SSc-ILD at Scleroderma centres in the US.
Not one 🫁 MD on this paper 👀
Are Rheumatologists treating/managing ILD at your centres?
@jskim8223.bsky.social @ipfdoc.bsky.social @tkulkarni.bsky.social @istamina.bsky.social
April 13, 2025 at 9:01 PM
Everybody can reply
1 reposts
8 likes
It's Day 17 of #RespMas! Behind today's #advent window is Richeldi L, et al. "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis" @nejm.org 2014. 370(22):2071-2082 (summarising INPULSIS-1 and INPULSIS-2) #RespEd #lungsky #medsky #pulmsky
December 17, 2024 at 8:28 AM
Everybody can reply
1 reposts
2 likes
Rebière et al. show that targeting CD9⁺ adipose progenitors with nintedanib+celecoxib reduces adipose fibrosis in obesity. Interesting, clinically relevant paper @cp-cellrepmed.bsky.social from the labs of Emmanuel Gautier, Karine Clément & Geneviève Marcelin: doi.org/10.1016/j.xc... 🧪
Combined pharmacological targeting of CD9+ progenitors alleviates obesity-induced adipose tissue fibrosis and metabolic impairment
Fibrosis in visceral white adipose tissue (vWAT) is closely associated with tissue dysfunction and systemic metabolic disturbances in obesity. Identif…
doi.org
July 31, 2025 at 8:31 AM
Everybody can reply
#Clophosphamid oder #Mycophenolat-Mofetil, antifibrotische Therapie mit #Nintedanib So, nun kommen Gedanken zur #Gesundheit Die erstgenannten Medikamente sind für die #Autoimmunerkrankung, das letztgenannte fur die diagnostizierte Lungenbeschädigung. Wie sind die Erfahrungen mit den Medikamenten? /
June 13, 2025 at 5:07 PM
Everybody can reply
UAB study of 47 RA-ILD pts (Dx Age 64.7 yrs; 30 mos F/U). Median 100 mos from RA Dx to RA-ILD. Half (49%) recv Rx for RA-ILD; few w/ TCZ, nintedanib, pirfenidone. ~90% had RA-ILD stability/improve @ 6 & 12 mos. Progression assoc w/ smoking (P .025) @ 6 mos only. pmc.ncbi.nlm.nih.gov/articles/PMC...
Profile of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Single-Center Study
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a well-described complication of rheumatoid arthritis (RA). The authors sought to describe the characteristics, treatment…
pmc.ncbi.nlm.nih.gov
September 11, 2025 at 7:15 PM
Everybody can reply
1 likes
Through Thick & Thin 500 is an RCT question:
The SENSCIS trial investigating nintedanib
#ACR25 #KnowledgeBowl
The SENSCIS trial investigating nintedanib
#ACR25 #KnowledgeBowl
October 26, 2025 at 6:36 PM
Everybody can reply
A case of idiopathic pulmonary fibrosis with suspected drug-induced lung injury following acute exacerbation after Nintedanib administration
A case of idiopathic pulmonary fibrosis with suspected drug-induced lung injury following acute exacerbation after Nintedanib administration
A 74-year-old man was treated with nintedanib for idiopathic pulmonary fibrosis (IPF). Thirty-six days after starting to take nintedanib, he admitted to our hospital due to respiratory failure with ground-glass opacities and mediastinal emp...
eurekamag.com
July 21, 2025 at 7:32 AM
Everybody can reply
Curious why market isn't responding positively to PureTech's ELEVATE IPF results - is it because comparator was pirfenidone and benefit might not stack up against nintedanib? #lungsky
December 18, 2024 at 4:13 PM
Everybody can reply
Nerandomilast slows FVC deterioration in IPF patients without/with background #antifibrotic therapy.
- No additional protection from IPF exacerbation
- Pirfenidone decreases plasma levels of Nerandomilast by 50% as opposed to nintedanib.
#pulmonaryfibrosis #ATS2025
www.nejm.org/doi/full/10....
- No additional protection from IPF exacerbation
- Pirfenidone decreases plasma levels of Nerandomilast by 50% as opposed to nintedanib.
#pulmonaryfibrosis #ATS2025
www.nejm.org/doi/full/10....
May 19, 2025 at 12:26 PM
Everybody can reply
1 likes
mRSS Robinson 200:
These are the two FDA approved drugs for the treatment of SSc -> What are nintedanib and tocilizumab?
#ACR25 #KnowledgeBowl
These are the two FDA approved drugs for the treatment of SSc -> What are nintedanib and tocilizumab?
#ACR25 #KnowledgeBowl
October 26, 2025 at 7:44 PM
Everybody can reply
"Human medicines European public assessment report (EPAR): Nintedanib Viatris, nintedanib, Status: Opinion"
#Health #Healthcare #ElderCare #MedSky
#Health #Healthcare #ElderCare #MedSky
Human medicines European public assessment report (EPAR): Nintedanib Viatris, nintedanib, Status: Opinion
Human medicines European public assessment report (EPAR): Nintedanib Viatris, nintedanib, Status: Opinion
www.ema.europa.eu
June 20, 2025 at 11:02 AM
Everybody can reply
Successful #Tepotinib Treatment in MET Exon 14 Skipping Mutation-Positive Lung #Adenocarcinoma With Idiopathic Pulmonary Fibrosis Through #Nintedanib Combination
onlinelibrary.wiley.com/doi/10.1002/...
#IPF
onlinelibrary.wiley.com/doi/10.1002/...
#IPF
July 7, 2025 at 3:00 AM
Everybody can reply
🤖 Automated message
9 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2025-03-24.html
Changes: nintedanib esilate, enzalutamide, filgrastim, pirfenidone, azathioprine, fingolimod hydrochloride
9 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2025-03-24.html
Changes: nintedanib esilate, enzalutamide, filgrastim, pirfenidone, azathioprine, fingolimod hydrochloride
March 24, 2025 at 3:23 PM
Everybody can reply
💊🫁Therapies in CTD-ILD (ATS 2020):
🔹Steroids- acute inflammation
🔹Mycophenolate/Cyclophosphamide- immunosuppression backbone
🔹Rituximab/Tacrolimus- for refractory disease
🔹Nintedanib/Tocilizumab- antifibrotic & targeted
#ILD #PulmCC @atscommunity.bsky.social
tinyurl.com/kyyvnftu
🔹Steroids- acute inflammation
🔹Mycophenolate/Cyclophosphamide- immunosuppression backbone
🔹Rituximab/Tacrolimus- for refractory disease
🔹Nintedanib/Tocilizumab- antifibrotic & targeted
#ILD #PulmCC @atscommunity.bsky.social
tinyurl.com/kyyvnftu
October 25, 2025 at 11:42 PM
Everybody can reply
Clophosphamid oder Mycophenolat-Mofetil für die #Autoimmunerkrankung und Nintedanib für meine kaputte Lunge. Ich bin gespannt & lasse mich überraschen.
June 17, 2025 at 8:18 AM
Everybody can reply
📰 New: Case Report
Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years
This case suggests serological remission and improvement of pulmonary fibrosis as viable goals
🔗 tinyurl.com/mpmtctma
Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years
This case suggests serological remission and improvement of pulmonary fibrosis as viable goals
🔗 tinyurl.com/mpmtctma
May 30, 2025 at 9:07 AM
Everybody can reply
1 likes
Clinical study confirms tissue stiffening in breast cancer can drive metastasis - ecancer
A study published in Clinical Cancer Research confirmed that tissue stiffening in the most common types of breast cancer, HER2-negative, can directly
ecancer.org
January 20, 2025 at 5:10 AM
Everybody can reply
Now can we use CA-125 as a theragnostic biomarker of treatment response in patients with IPF? Why wouldn't we?
@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
pmc.ncbi.nlm.nih.gov/articles/pmi...
@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
pmc.ncbi.nlm.nih.gov/articles/pmi...
December 21, 2024 at 6:52 AM
Everybody can reply
6 reposts
10 likes
Transcriptomic analysis reveals lipid metabolism and macrophage involvement associated with nintedanib treatment in a rat bleomycin model https://www.biorxiv.org/content/10.1101/2024.10.30.620876v1
Transcriptomic analysis reveals lipid metabolism and macrophage involvement associated with nintedanib treatment in a rat bleomycin model https://www.biorxiv.org/content/10.1101/2024.10.30.620876v1
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible lung disease wit
www.biorxiv.org
November 4, 2024 at 5:02 AM
Everybody can reply
1 likes
Had the same question when I saw this paper- typically co-manage SSc patients with our rheumatology colleagues and ILD team are predominant prescribers for Nintedanib.
April 14, 2025 at 9:05 PM
Everybody can reply
1 likes
Super interesting paper and study. Did we need the placebo group? Would pre-post have been enough? Just wondering since I would feel bad about keeping my IPF patient off of nintedanib for three months.
December 22, 2024 at 4:59 AM
Everybody can reply
1 likes
🤖 Automated message
10 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2025-03-04.html
Changes: nintedanib esilate, bevacizumab, eculizumab
10 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2025-03-04.html
Changes: nintedanib esilate, bevacizumab, eculizumab
March 4, 2025 at 3:23 PM
Everybody can reply
Nintedanib Esylate Soft Capsules (KeChangDa®) – 150 mg Wholesale price comparison
Nintedanib is a small-molecule triple angiokinase inhibitor targeting VEGFR 1–3, PDGFR α/β, FGFR 1–3, along with select non-receptor kinases (Src, Lck, Lyn). Approved in China (NMPA No. H20233582;…
Nintedanib is a small-molecule triple angiokinase inhibitor targeting VEGFR 1–3, PDGFR α/β, FGFR 1–3, along with select non-receptor kinases (Src, Lck, Lyn). Approved in China (NMPA No. H20233582;…
Nintedanib Esylate Soft Capsules (KeChangDa®) – 150 mg Wholesale price comparison
Nintedanib is a small-molecule triple angiokinase inhibitor targeting VEGFR 1–3, PDGFR α/β, FGFR 1–3, along with select non-receptor kinases (Src, Lck, Lyn). Approved in China (NMPA No. H20233582; Code 86902180002778), manufactured by Sichuan Kelun Pharmaceutical Co., Ltd. Strictly for laboratory research use（Please consult the staff for other purposes）
arizona-mall.com
June 20, 2025 at 6:54 AM
Everybody can reply
🧵5️⃣ ⚡️Therapeutic modality to improve antifibrotic efficacy⚡️
📌Systems #pharmacology reveals that #zevaquenabant and #nintedanib treatments reverse distinct and shared #pulmonaryfibrosis related pathways, provides opportunity for future clinical trials to improve clinical efficacy.
📌Systems #pharmacology reveals that #zevaquenabant and #nintedanib treatments reverse distinct and shared #pulmonaryfibrosis related pathways, provides opportunity for future clinical trials to improve clinical efficacy.
July 3, 2025 at 6:20 PM
Everybody can reply